Broad-Spectrum Small Molecule Antibiotics for MDR Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of antibiotic resistance in bacterial pathogens has led to a gap in the development of new antibiotics, with existing antibiotics targeting only a few specific pathways and bacteria quickly developing resistance, limiting treatment options for multidrug-resistant infections.
Innovation Solution
Development of small molecule compounds with broad-spectrum antibacterial activity that inhibit essential bacterial proteins or signaling pathways, particularly targeting fatty acid biosynthesis, to inhibit bacterial growth and treat infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics target specific pathways, then treatment effectiveness is maintained, but bacterial resistance develops quickly limiting treatment options
Solution Approach 1:
The patent applies universality by designing antibiotics that can target multiple bacterial pathways simultaneously, including cell wall synthesis, protein synthesis, and DNA replication. This multi-target approach ensures that if bacteria develop resistance to one mechanism, the other pathways remain effective, thereby maintaining treatment effectiveness while expanding treatment options for multidrug-resistant infections.
Solution Approach 2:
The patent employs composite materials by combining multiple functional groups within a single antibiotic molecule, creating a synergistic effect where different chemical moieties target different bacterial processes. This composite structure enables the antibiotic to disrupt multiple bacterial functions concurrently, preventing the development of resistance and providing versatile treatment options.
2Adaptability or versatility
If new antibiotics are developed to address resistance, then treatment options expand, but the number of new antibiotics in discovery pipeline has decreased
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular structures, chemical properties, and pharmacological parameters of antibiotic compounds to optimize their activity against resistant bacteria. By adjusting these parameters, the patent identifies novel antibiotics with enhanced efficacy and reduced resistance potential, thereby increasing the rate of successful new antibiotic discovery.
Solution Approach 2:
The patent employs copying by creating analogs and derivatives of existing antibiotic structures, modifying them to overcome resistance mechanisms while maintaining therapeutic effectiveness. This approach allows rapid generation of new antibiotic candidates based on proven successful structures, accelerating the discovery pipeline.
3Duration of action of moving object
If antibiotics are used for short-term treatment, then patient response is improved, but the best antibiotics are kept on shelf to save for last resort
Solution Approach 1:
The patent applies segmentation by developing a pipeline of antibiotics with varying durations and strengths, allowing clinicians to segment treatment strategies based on infection severity and bacterial resistance profiles. This enables short-term use of novel antibiotics for severe infections while reserving traditional antibiotics for less severe cases, optimizing both treatment effectiveness and bacterial preservation.
Data Source
AI summary
Antibiotic resistance, by definition, occurs when a bacterial pathogen is no longer effectively treated with a particular drug when formerly it was. With the rise in resistance and public awareness of “superbugs,” there is a need for new antibiotics, but the number of new antibiotics in the discovery pipeline is roughly a tenth of what it was in the 1980s. Bacterial resistance has emerged, evolved, or has been transmitted to confer resistance to every marketed drug available. Multidrug resistant (MDR) infections have been identified in hospitals that are resistant to all available antibiotics. Resistance is often observed within 2 years of marketing a new antibiotic. Described herein are antibiotic compounds for use in inhibiting bacterial growth and/or treating or preventing a bacterial infection in a subject.